Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Akanksha Dua"'
Autor:
Patrice Joseph, Rochelle Sun, Colette Guiteau, Marc Antoine Jean Juste, Nancy Dorvil, Stalz Vilbrun, Rode Secours, Karine Severe, Parnel Raymond, Fernande Cetoute, Wilnide Jean Baptiste, Guyrlaine Forestal, Stanley Cadet, Adias Marcelin, Marie Marcelle Deschamps, Margaret L. McNairy, Akanksha Dua, Hoi Ching Cheung, Jean William Pape, Serena P. Koenig
Publikováno v:
The Lancet Regional Health. Americas, Vol 37, Iss , Pp 100847- (2024)
Summary: Background: There are limited data on the effectiveness of differentiated service delivery (DSD) for HIV care during sociopolitical turmoil. We assessed outcomes with a DSD model of care that includes patient choice between community-based a
Externí odkaz:
https://doaj.org/article/ac4f421d34c54ef4a02762c5195a0d73
Autor:
Damemarie Paul, Elyse Swallow, Oscar Patterson-Lomba, Tychell Branchcomb, Laetitia N’Dri, Andres Gomez-Lievano, Jingyi Liu, Akanksha Dua, Marisa McGinley
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Several oral disease-modifying therapies (DMTs) have been approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). In the absence of head-to-head randomized data, matching-adjusted i
Externí odkaz:
https://doaj.org/article/f3c41c1c41254ef0bed8f54b525d2363
Autor:
Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, Elyse Swallow, Akanksha Dua, Komal Gupte-Singh
Publikováno v:
Neurology and Therapy, Vol 12, Iss 3, Pp 849-861 (2023)
Abstract Introduction This study assessed the cost-effectiveness of ozanimod compared with commonly used disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS). Methods Annualized relapse rate (ARR) and safety data wer
Externí odkaz:
https://doaj.org/article/588434fe896a44eea40acf33edf79a02
Autor:
Mirko Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutati
Externí odkaz:
https://doaj.org/article/7754d2c3a2fb47a9bd75569fd3c08e6a
Autor:
Priyanka Bobbili, Kellie Ryan, Maral DerSarkissian, Akanksha Dua, Christopher Yee, Mei Sheng Duh, Jorge E Gomez
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0230444 (2020)
INTRODUCTION:Concurrent chemoradiotherapy (cCRT) was the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) prior to the PACIFIC trial, however, patients also received single modality therapy. This study iden
Externí odkaz:
https://doaj.org/article/43907878242845e3adc39885f1a16f06
Autor:
Mirko Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Publikováno v:
BMC cancer. 22(1)
Background Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. Howe
Autor:
Kathryn M. Dupnik, Oksana Ocheretina, Alexandra Apollon, Sean E Collins, Margaret L. McNairy, Patrice Severe, Marc Antoine Jean-Juste, Serena P. Koenig, Zhiwen Yao, Akanksha Dua, Anthony Byrne, Heejung Bang, Jean W. Pape, Etienne Cremieux, Yvetot Joseph
Publikováno v:
Journal of the International AIDS Society
Introduction Long‐term mortality among TB survivors appears to be higher than control populations without TB in many settings. However, data are limited among persons with HIV (PWH). We assessed the association between cured TB and long‐term mort
Autor:
Kellie Ryan, Akanksha Dua, Mei Sheng Duh, Melissa Pavilack, Priyanka Bobbili, Ancilla W. Fernandes, Jorge Gomez
Publikováno v:
Future oncology (London, England). 15(29)
Aim: To analyze treatment patterns and overall survival (OS) across time (2009–2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy w
Autor:
Antonia Ridolfi, Fabrice Andre, Akanksha Dua, Mirko Fillbrunn, Hope S. Rugo, James Signorovitch, Ines Lorenzo, Ruchuan Wang, Jinhee Park
Publikováno v:
Journal of Clinical Oncology. 38:1069-1069
1069 Background: Approximately 40% of HR+/HER2- mBC patients harbor PIK3CA mutation. Associations between PIK3CA mutation status and clinical outcomes among patients with HR+/HER2- mBC have been heterogeneous across clinical trials. We synthesized av
Publikováno v:
Journal of Clinical Oncology. 37:e18191-e18191
e18191 Background: While concurrent chemoradiotherapy (cCRT) is standard of care for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC), some pts receive single modality therapy. This study identified predictors of therapy